{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-010097","form_type":"8-K","ticker":"SMTI","cik":"0000714256","company_name":"Sanara MedTech Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.077941+00:00","generated_at":"2026-05-21T11:26:08.752860+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sanara MedTech Q1 revenue up 26% to $23.4M; net loss widens to $3.5M","bullets":["Net revenue $23.4M (+26% YoY); net loss $3.5M vs $1.8M loss in Q1 2024.","Adjusted EBITDA improved to $0.7M from $0.3M; gross margin 92% vs 90%.","Sanara Surgical revenue drove growth; segment net loss $0.6M; Tissue Health Plus loss $2.9M.","Borrowed $12.25M under amended CRG term loan; $12.25M additional available through Dec 2025.","Appointed Elizabeth Taylor CFO; exclusive BMI license for OsStic bone void filler and ARC technology."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-010097","json":"https://secwatch.observer/filing/0001641172-25-010097.json","markdown":"https://secwatch.observer/filing/0001641172-25-010097.md","text":"https://secwatch.observer/filing/0001641172-25-010097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/714256/000164117225010097/0001641172-25-010097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/714256/000164117225010097/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T11:26:08.752860+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}